Cargando…
Vitamin D deficiency 2.0: an update on the current status worldwide
Vitamin D testing and the use of vitamin D supplements have increased substantially in recent years. Currently, the role of vitamin D supplementation, and the optimal vitamin D dose and status, is a subject of debate, because large interventional studies have been unable to show a clear benefit (in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091696/ https://www.ncbi.nlm.nih.gov/pubmed/31959942 http://dx.doi.org/10.1038/s41430-020-0558-y |
_version_ | 1783510048485408768 |
---|---|
author | Amrein, Karin Scherkl, Mario Hoffmann, Magdalena Neuwersch-Sommeregger, Stefan Köstenberger, Markus Tmava Berisha, Adelina Martucci, Gennaro Pilz, Stefan Malle, Oliver |
author_facet | Amrein, Karin Scherkl, Mario Hoffmann, Magdalena Neuwersch-Sommeregger, Stefan Köstenberger, Markus Tmava Berisha, Adelina Martucci, Gennaro Pilz, Stefan Malle, Oliver |
author_sort | Amrein, Karin |
collection | PubMed |
description | Vitamin D testing and the use of vitamin D supplements have increased substantially in recent years. Currently, the role of vitamin D supplementation, and the optimal vitamin D dose and status, is a subject of debate, because large interventional studies have been unable to show a clear benefit (in mostly vitamin D replete populations). This may be attributed to limitations in trial design, as most studies did not meet the basic requirements of a nutrient intervention study, including vitamin D-replete populations, too small sample sizes, and inconsistent intervention methods regarding dose and metabolites. Vitamin D deficiency (serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L or 20 ng/ml) is associated with unfavorable skeletal outcomes, including fractures and bone loss. A 25(OH)D level of >50 nmol/L or 20 ng/ml is, therefore, the primary treatment goal, although some data suggest a benefit for a higher threshold. Severe vitamin D deficiency with a 25(OH)D concentration below <30 nmol/L (or 12 ng/ml) dramatically increases the risk of excess mortality, infections, and many other diseases, and should be avoided whenever possible. The data on a benefit for mortality and prevention of infections, at least in severely deficient individuals, appear convincing. Vitamin D is clearly not a panacea, and is most likely efficient only in deficiency. Given its rare side effects and its relatively wide safety margin, it may be an important, inexpensive, and safe adjuvant therapy for many diseases, but future large and well-designed studies should evaluate this further. A worldwide public health intervention that includes vitamin D supplementation in certain risk groups, and systematic vitamin D food fortification to avoid severe vitamin D deficiency, would appear to be important. In this narrative review, the current international literature on vitamin D deficiency, its relevance, and therapeutic options is discussed. |
format | Online Article Text |
id | pubmed-7091696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70916962020-03-24 Vitamin D deficiency 2.0: an update on the current status worldwide Amrein, Karin Scherkl, Mario Hoffmann, Magdalena Neuwersch-Sommeregger, Stefan Köstenberger, Markus Tmava Berisha, Adelina Martucci, Gennaro Pilz, Stefan Malle, Oliver Eur J Clin Nutr Review Article Vitamin D testing and the use of vitamin D supplements have increased substantially in recent years. Currently, the role of vitamin D supplementation, and the optimal vitamin D dose and status, is a subject of debate, because large interventional studies have been unable to show a clear benefit (in mostly vitamin D replete populations). This may be attributed to limitations in trial design, as most studies did not meet the basic requirements of a nutrient intervention study, including vitamin D-replete populations, too small sample sizes, and inconsistent intervention methods regarding dose and metabolites. Vitamin D deficiency (serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L or 20 ng/ml) is associated with unfavorable skeletal outcomes, including fractures and bone loss. A 25(OH)D level of >50 nmol/L or 20 ng/ml is, therefore, the primary treatment goal, although some data suggest a benefit for a higher threshold. Severe vitamin D deficiency with a 25(OH)D concentration below <30 nmol/L (or 12 ng/ml) dramatically increases the risk of excess mortality, infections, and many other diseases, and should be avoided whenever possible. The data on a benefit for mortality and prevention of infections, at least in severely deficient individuals, appear convincing. Vitamin D is clearly not a panacea, and is most likely efficient only in deficiency. Given its rare side effects and its relatively wide safety margin, it may be an important, inexpensive, and safe adjuvant therapy for many diseases, but future large and well-designed studies should evaluate this further. A worldwide public health intervention that includes vitamin D supplementation in certain risk groups, and systematic vitamin D food fortification to avoid severe vitamin D deficiency, would appear to be important. In this narrative review, the current international literature on vitamin D deficiency, its relevance, and therapeutic options is discussed. Nature Publishing Group UK 2020-01-20 2020 /pmc/articles/PMC7091696/ /pubmed/31959942 http://dx.doi.org/10.1038/s41430-020-0558-y Text en © The Author(s), under exclusive licence to Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Amrein, Karin Scherkl, Mario Hoffmann, Magdalena Neuwersch-Sommeregger, Stefan Köstenberger, Markus Tmava Berisha, Adelina Martucci, Gennaro Pilz, Stefan Malle, Oliver Vitamin D deficiency 2.0: an update on the current status worldwide |
title | Vitamin D deficiency 2.0: an update on the current status worldwide |
title_full | Vitamin D deficiency 2.0: an update on the current status worldwide |
title_fullStr | Vitamin D deficiency 2.0: an update on the current status worldwide |
title_full_unstemmed | Vitamin D deficiency 2.0: an update on the current status worldwide |
title_short | Vitamin D deficiency 2.0: an update on the current status worldwide |
title_sort | vitamin d deficiency 2.0: an update on the current status worldwide |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091696/ https://www.ncbi.nlm.nih.gov/pubmed/31959942 http://dx.doi.org/10.1038/s41430-020-0558-y |
work_keys_str_mv | AT amreinkarin vitaminddeficiency20anupdateonthecurrentstatusworldwide AT scherklmario vitaminddeficiency20anupdateonthecurrentstatusworldwide AT hoffmannmagdalena vitaminddeficiency20anupdateonthecurrentstatusworldwide AT neuwerschsommereggerstefan vitaminddeficiency20anupdateonthecurrentstatusworldwide AT kostenbergermarkus vitaminddeficiency20anupdateonthecurrentstatusworldwide AT tmavaberishaadelina vitaminddeficiency20anupdateonthecurrentstatusworldwide AT martuccigennaro vitaminddeficiency20anupdateonthecurrentstatusworldwide AT pilzstefan vitaminddeficiency20anupdateonthecurrentstatusworldwide AT malleoliver vitaminddeficiency20anupdateonthecurrentstatusworldwide |